← Back to Thought Leadership

Blog

Pharma Network Design for Consumer Health Goods: Seven Challenges a Decision Engine Can Answer

The Consumer Health Goods industry encompasses products that promote health and well-being, including OTC (Over-The-Counter) medications, nutritional supplements, cosmetics, and personal care products. Operating at the intersection of pharmaceutical and consumer packaged goods (CPG) sectors, this industry combines strict regulatory requirements with consumer-driven dynamics, creating unique pharma network design challenges.

These businesses must navigate dynamic market conditions, manage intricate supply chains, and balance stringent quality standards with cost efficiency, all while meeting consumer expectations and maintaining profitability. Every one of those trade-offs ends in a decision, and leadership needs to know that decision is the right one, not just a plausible one.

Strategic pharma network design has become essential for overcoming these challenges and achieving sustainable growth. This blog looks at the top 7 challenges Consumer Health Goods companies face in designing and optimizing their supply chain networks to build resilience.

Top 7 Pharma Network Design Challenges for Consumer Health Goods Companies

1. Balancing Cost and Service

Striking the right balance between cost efficiency and service levels is critical in Consumer Health Goods. Companies face strict quality requirements, short shelf lives, and fluctuating demand. Rising transportation costs, labor shortages, and geopolitical disruptions further complicate efforts to optimize production and distribution networks while ensuring timely and high-quality deliveries.

2. Adapting to Market Shifts

Consumer health markets are highly dynamic, driven by changing consumer preferences, product innovation, and regulatory updates. Rapid introduction of new products, entry into new markets, or shifts in consumer demand can render existing pharma network designs obsolete. Companies need agile supply chain models capable of quickly adapting to these shifts without incurring excessive costs or operational disruptions.

3. Managing Capacity Constraints

Capacity planning is critical for ensuring that production and distribution networks can meet current and future demand. However, many companies struggle with:

  • Identifying underutilized or overutilized assets across their network.
  • Planning for market growth without overinvesting in new infrastructure.
  • Determining the optimal timing for capacity expansions, particularly when considering alternative suppliers.

4. Weighing the Financial Impact of Decisions

Network optimization often requires significant investments in new facilities, technology upgrades, or alternative suppliers. Companies must weigh the financial impact of these investments, considering metrics such as Net Present Value (NPV), Internal Rate of Return (IRR), and free cash flow. Ensuring these decisions align with long-term business objectives adds another layer of complexity.

5. Balancing Internal vs. External Manufacturing

Deciding the right mix of in-house and external manufacturing can be daunting. Internal production offers greater control over quality and lead times but requires significant capital investment. Outsourcing, on the other hand, can provide flexibility and cost savings but often comes with supplier reliability and quality management risks. Companies need data-driven insights to strike the optimal balance.

6. Scenario Modeling and Decision Complexity

Traditional tools like Excel are no longer sufficient for managing the complexities of modern pharma network design. Companies must evaluate multiple scenarios, such as shifting production between sites, incorporating new acquisitions, or divesting business units, to understand their financial and operational impacts. Without a model that enforces every constraint, these evaluations take days, invite errors, and lead to suboptimal decisions that no one can fully explain.

7. Sustainability and Regulatory Compliance

Sustainability has become a critical consideration for network design in pharma and consumer health goods. Companies are under increasing pressure to reduce carbon emissions, optimize energy usage, and minimize waste. At the same time, they must navigate stringent regulations around product safety, traceability, and environmental impact. Balancing these priorities while maintaining profitability requires innovative approaches to network optimization.

Solving Pharma Network Design Challenges with a Decision Engine

These challenges are significant, but they are not unbeatable. They share a common thread: each one is a decision with many interacting constraints, and the answer has to hold up in front of finance, quality, and regulators.

River Logic's Enterprise Optimizer® (EO) Decision Engine has helped leading companies in this space by optimizing investment decisions with robust financial modeling, balancing in-house and external manufacturing efficiently, adapting to market shifts and regulatory changes with agility, and designing sustainable networks that align with corporate and sustainability goals.

The EO Decision Engine works from one model of your business. Build it once, and the same model answers network design, capacity, make-vs-buy, and capital allocation questions without rebuilding. Each recommendation is provably optimal, not a heuristic, and comes with the receipt: the binding constraint behind it and a trace back to the source data. Scenarios that once took days run in hours.

Network design is critical to success in the Consumer Health Goods industry. By addressing these top challenges with a decision engine and strategic planning, companies can build resilient and adaptive supply chain networks that support long-term growth and profitability.

Ready to see it on your network? Schedule a demo of the EO Decision Engine.

Watch How EO Decision Engine Works

Our Customers & Partners

Merck
PwC
Accenture
Microsoft
Gurobi
Kenvue
Georgia-Pacific
Bristol Myers Squibb
Tronox
ToolsGroup
ZS
McKee Foods
Philip Morris International
Yorkshire Water
Brookes
AlixPartners
Finstock
BMA
Tengler
Transnova
Cornerstone
Tarmac
Boise
Merck
PwC
Accenture
Microsoft
Gurobi
Kenvue
Georgia-Pacific
Bristol Myers Squibb
Tronox
ToolsGroup
ZS
McKee Foods
Philip Morris International
Yorkshire Water
Brookes
AlixPartners
Finstock
BMA
Tengler
Transnova
Cornerstone
Tarmac
Boise